RET-rearranged spindle cell soft tissue sarcoma in children: description of a clinical case and literature review
Authors:
- O. S. ZatsarinnayaOZO. S. Zatsarinnaya
- A. E. DruyADA. E. Druy
- D. M. KonovalovDKD. M. Konovalov
- N. A. AndreevaNAN. A. Andreeva
- A. V. PanferovaAPA. V. Panferova
- A. S. SharlaiASA. S. Sharlai
- K. Yu. SinichenkovaKSK. Yu. Sinichenkova
- T. V. ShamanskayaTST. V. Shamanskaya
- V. Yu. RoshchinVRV. Yu. Roshchin
- A. P. ShcherbakovASA. P. Shcherbakov
- N. A. BolshakovNBN. A. Bolshakov
- D. Yu. KachanovDKD. Yu. Kachanov
Open Access
- 2 November 2025
- journal article
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 103-112
Abstract
Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.Keywords
This publication has 23 references indexed in Scilit:
- Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET FusionsLaboratory Investigation, 2023
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trialThe Lancet Oncology, 2022
- Precision therapy for RET-altered cancers with RET inhibitorsTrends in Cancer, 2021
- RASAL2-RET: a novel RET rearrangement in a patient with high-grade sarcoma of the chestAnnals of Oncology, 2020
- Aberrant receptor tyrosine kinase signaling in lipofibromatosis: a clinicopathological and molecular genetic study of 20 casesLaboratory Investigation, 2019
- Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategyLaboratory Investigation, 2018
- A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusionPediatric Blood & Cancer, 2016
- A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinomaNature Reviews Endocrinology, 2016
- RET revisited: expanding the oncogenic portfolioNature Reviews Cancer, 2014
- Ret-Dependent Cell Rearrangements in the Wolffian Duct Epithelium Initiate Ureteric Bud MorphogenesisDevelopmental Cell, 2009